KR20150036235A - 트리-염 형태의 메트포민 - Google Patents

트리-염 형태의 메트포민 Download PDF

Info

Publication number
KR20150036235A
KR20150036235A KR20157002264A KR20157002264A KR20150036235A KR 20150036235 A KR20150036235 A KR 20150036235A KR 20157002264 A KR20157002264 A KR 20157002264A KR 20157002264 A KR20157002264 A KR 20157002264A KR 20150036235 A KR20150036235 A KR 20150036235A
Authority
KR
South Korea
Prior art keywords
metformin
compound
formula
subject
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157002264A
Other languages
English (en)
Korean (ko)
Inventor
바나바라 엘. 밀라리
프랭크 씨. 스시아볼리노
Original Assignee
테티스 파마수티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by 테티스 파마수티컬스 엘엘씨 filed Critical 테티스 파마수티컬스 엘엘씨
Publication of KR20150036235A publication Critical patent/KR20150036235A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR20157002264A 2012-07-10 2013-07-10 트리-염 형태의 메트포민 Withdrawn KR20150036235A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US61/669,763 2012-07-10
US201261670368P 2012-07-11 2012-07-11
US201261670376P 2012-07-11 2012-07-11
US61/670,376 2012-07-11
US61/670,368 2012-07-11
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
US13/841,970 2013-03-15
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (1)

Publication Number Publication Date
KR20150036235A true KR20150036235A (ko) 2015-04-07

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157002264A Withdrawn KR20150036235A (ko) 2012-07-10 2013-07-10 트리-염 형태의 메트포민

Country Status (12)

Country Link
EP (1) EP2872483A4 (enExample)
JP (1) JP2015523382A (enExample)
KR (1) KR20150036235A (enExample)
CN (1) CN104684889A (enExample)
AU (1) AU2013290168A1 (enExample)
BR (1) BR112015000368A2 (enExample)
CA (1) CA2878819A1 (enExample)
IL (1) IL236613A0 (enExample)
IN (1) IN2015KN00076A (enExample)
MX (1) MX2015000408A (enExample)
WO (1) WO2014011814A1 (enExample)
ZA (1) ZA201500274B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
EA201692548A1 (ru) * 2014-06-18 2017-10-31 ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Минеральные аминокислотные комплексы активных веществ
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
CN100415224C (zh) * 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
CN101855204B (zh) * 2007-09-21 2013-09-11 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
EP2229158B1 (en) * 2007-12-20 2016-08-10 Fertin Pharma A/S Compressed chewing gum tablet
US20110082119A1 (en) * 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2012054523A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes

Also Published As

Publication number Publication date
WO2014011814A1 (en) 2014-01-16
EP2872483A4 (en) 2016-03-16
IL236613A0 (en) 2015-02-26
ZA201500274B (en) 2017-10-25
BR112015000368A2 (pt) 2017-06-27
EP2872483A1 (en) 2015-05-20
IN2015KN00076A (enExample) 2015-07-31
CN104684889A (zh) 2015-06-03
AU2013290168A1 (en) 2015-02-05
JP2015523382A (ja) 2015-08-13
CA2878819A1 (en) 2014-01-16
MX2015000408A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
KR20150036235A (ko) 트리-염 형태의 메트포민
US7973073B2 (en) Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
US8765811B2 (en) Tri-salt form of metformin
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
JP2013516461A (ja) ビグアニド誘導体、その製造方法及びこれを有効成分として含有する薬学組成物
SK14922002A3 (sk) Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
TWI522109B (zh) 蕨素化合物用於治療糖尿病及肥胖之用途
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
MX2009001104A (es) Derivados de 4-trimetilamonio-3-aminobutirato y 4-trimetilfosfonio-3-aminobutirato como inhibidores de carnitina palmitoil transferasa.
TW516959B (en) Composition containing ascorbic acid
US9382187B2 (en) Tri-salt form of metformin
CN104557944B (zh) 一种降糖药物及其制备方法
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
EP2139320A1 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
US20110060156A1 (en) Pyruvate Derivatives with Neuroprotective Effect, Process for Preparing the Same and Pharmaceutical Composition Comprising the Same
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
US20080280985A1 (en) Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US20090176835A1 (en) Pharmaceutical composition for suppression of the expression of atp citrate lyase and use thereof
EP1547614B1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
WO2024062395A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating metabolic syndrome
NZ618801A (en) Substituted cinnamamide derivative, preparation method and use thereof
NZ618801B2 (en) Substituted cinnamamide derivative, preparation method and use thereof
HK1137446A (en) Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid